BioAge Labs, Inc. (BIOA) AI Stock Analysis

• Market Cap: $160.97M
• Dividend Yield: N/A
• Average Volume (3M): 265.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 62
• Sector: Healthcare
• Sector Strength: 58
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -2.03
• Shares Outstanding: 35,850,037
• 10 Day Avg. Volume: 451,692
• 30 Day Avg. Volume: 265,821
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.16
• Enterprise Value/Revenue: -17.35
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.10
• 1Y Price Target: $5.67
• Price Target Upside: 26.28% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 33 Underperform
• Price Target: ―

BioAge Labs, Inc. is facing critical financial difficulties, characterized by no revenue generation, increasing losses, and dependence on external financing. The technical indicators suggest a bearish trend, and the lack of valuation metrics such as P/E ratio and dividend yield complicates valuation. These factors collectively reflect a weak overall stock performance.

Positive Factors

Financial Position

BioAge ended the first quarter with $335.1 million in cash, and the company's balance sheet is expected to fund operations through at least 2029.

Research and Development

BGE-102 continues to advance towards Phase 1 SAD data, indicating progress in the company's pipeline.

Strategic Partnerships

BioAge announced an option agreement with JiKang Therapeutics to in-license a novel APJ agonist antibody.

Negative Factors

Clinical Data Uncertainty

There is a lack of robust clinical data to support the hypothesis of NLRP3 inhibition as a therapeutic weight management strategy.

Program Discontinuation

The discontinuation of the lead azelaprag program due to the emergence of liver transaminitis is a notable update.

Stock Performance

BioAge shares are anticipated to remain somewhat range-bound over the next 12 months given limited stock-moving catalysts.

BioAge Labs, Inc. Business Overview & Revenue Model

Company Description

BioAge Labs, Inc. (BIOA) is a biotechnology company focused on developing innovative therapies aimed at extending healthy human lifespan by targeting the molecular pathways associated with aging. The company leverages its proprietary platform to identify and validate drug targets that can modulate key biological processes involved in aging. BioAge's core products include a pipeline of therapeutic candidates designed to treat age-related diseases and improve healthspan.

How the Company Makes Money

BioAge Labs, Inc. generates revenue primarily through partnerships and collaborations with pharmaceutical companies, as well as through research grants and funding. The company engages in strategic alliances to co-develop and commercialize its therapeutic candidates, which allows it to share development costs and potential profits. Additionally, BioAge may receive milestone payments and royalties from its partners as its drug candidates progress through clinical trials and, if successful, reach the market. The company may also rely on venture capital investments and public or private offerings to fund its research and development activities.

BioAge Labs, Inc. Financial Statement Overview

Summary

BioAge Labs, Inc. faces significant financial challenges, with no revenue generation and increasing losses impacting profitability. While the balance sheet has improved due to recent financing activities, the company's reliance on external funds and negative cash flows suggest ongoing financial instability. The company needs to address its revenue generation capabilities to improve its financial health.

Income Statement

BioAge Labs, Inc. has not generated any revenue over the past three years, impacting its ability to achieve positive profit margins. The company is experiencing increasing losses, as reflected in the negative EBIT and net income figures. This lack of revenue generation and increasing losses are significant concerns for the company's financial health.

Balance Sheet

The company's debt-to-equity position has improved significantly, transitioning from negative equity to a positive equity position in 2024, driven by increased financing activities. Despite this improvement, the company still carries some debt, which poses a risk. The equity ratio has improved to 90%, indicating a stronger balance sheet, but the company's reliance on external financing remains a concern.

Cash Flow

BioAge Labs, Inc. has been raising substantial funds, as seen from the positive financing cash flow. However, the company is still burning cash, with negative operating and free cash flows. The free cash flow growth rate remains negative, indicating ongoing operational cash challenges. The company's ability to sustain operations relies heavily on external financing, posing sustainability risks.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement		Total Revenue
1.45M	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00
	EBIT
-81.83M	-78.19M	-48.40M	-39.97M
	EBITDA
-73.28M	-78.19M	-55.90M	-39.35M
	Net Income Common Stockholders
-71.05M	-71.11M	-63.85M	-39.72M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
320.52M	354.35M	21.64M	27.64M
	Total Assets
343.84M	358.23M	25.92M	28.43M
	Total Debt
9.26M	8.70M	53.25M	2.47M
	Net Debt
-248.23M	-345.64M	31.61M	-25.18M
	Total Liabilities
30.67M	35.11M	199.32M	140.99M
	Stockholders Equity
313.17M	323.13M	-173.40M	-112.56M
Cash Flow		Free Cash Flow
-54.01M	-51.89M	-37.53M	-36.28M
	Operating Cash Flow
-53.21M	-51.52M	-37.36M	-36.18M
	Investing Cash Flow
-78.35M	-366.00K	-266.00K	-103.00K
	Financing Cash Flow
211.70M	381.20M	34.94M	2.50M

BioAge Labs, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DERM	62 Neutral	$160.97M	―	-48.14%	―	-29.69%	-105.88%
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
ASRT	53 Neutral	$59.09M	―	-25.19%	―	-16.23%	91.83%
ESPR	52 Neutral	$239.82M	―	23.44%	―	12.99%	17.78%
OPTN	50 Neutral	$97.22M	―	75.79%	―	10.58%	34.44%
IRWD	45 Neutral	$116.79M	85.74	-8.02%	―	-23.18%	97.12%
BIOA	33 Underperform	$160.97M	―	-30.20%	―	―	―